Combination Therapy Shows Potential in Psoriasis, Obesity
Overview
The TOGETHER-PsO trial demonstrated that ixekizumab plus tirzepatide significantly improved outcomes in adult patients with moderate to severe plaque psoriasis and obesity, achieving simultaneous complete skin clearance and at least 10% weight reduction at 36 weeks. The combination therapy outperformed ixekizumab alone in multiple efficacy endpoints.
Background
Psoriasis is a chronic inflammatory skin condition that can significantly impact quality of life, particularly in patients with comorbid obesity. The presence of obesity may reduce the effectiveness of psoriasis treatments, making it crucial to explore combination therapies that address both skin and weight management. The TOGETHER-PsO trial provides insights into the potential benefits of combining an IL-17A inhibitor with an anti-obesity agent.
Data Highlights
Group
Primary Endpoint Achieved
PASI 100
PASI 75 + 5% Weight Reduction
Weight Reduction ≥10%
Ixekizumab + Tirzepatide
27%
41%
80%
69%
Ixekizumab Alone
6%
29%
18%
9%
Key Findings
27% of participants receiving ixekizumab plus tirzepatide achieved the primary endpoint compared to 6% with ixekizumab alone.
41% of the combination group achieved PASI 100 versus 29% in the ixekizumab group.
Simultaneous PASI 75 and at least 5% weight reduction was observed in 80% of the combination group compared to 18% in the control group.
Mean body weight decreased by 15% in the combination group versus 1% in the ixekizumab group.
Gastrointestinal adverse events were more common in the combination therapy group, including nausea (25% vs 2%) and diarrhea (15% vs 2%).
No new safety concerns were identified, with serious adverse events occurring in 4% of the combination group.
Clinical Implications
The findings suggest that combining ixekizumab with tirzepatide may offer a dual benefit for patients with psoriasis and obesity, enhancing treatment efficacy. Clinicians should consider this combination therapy for eligible patients to improve both skin clearance and weight management outcomes.
Conclusion
The TOGETHER-PsO trial supports the use of ixekizumab plus tirzepatide as a promising treatment strategy for patients with moderate to severe psoriasis and obesity, demonstrating significant improvements in key clinical outcomes.
